Some very preliminary internet crumbs about a new possible rosacea treatment under development. The treatment under development is listed as a “novel tetracycline”.

Warner Chilcott Limited calls itself a “specialty pharmaceutical company, that engages in the development, manufacture, marketing, and sale of branded prescription pharmaceutical products in women’s healthcare and dermatology segments primarily in the United States”.

WC3035. In July 2007, we entered into an agreement with Paratek under which we acquired certain rights to novel tetracyclines under development for the treatment of acne and rosacea. Currently, we are working with Paratek to select a lead compound for development.

The 2009 annual report notes that a lead compound is currently in preclinical development.

We’ve seen novel antibiotics under development for rosacea in recent years. Collagenex, now owned by Galderma, was developing a “tetracycline which has no antibacterial activities but is a pure play anti-inflammatory, and it’s being targeted for the treatment of acne.” The product was called Incyclinide. This formulation of tetracycline was shelved as a rosacea treatment when it was discovered that a 40mg dose causes photo-toxicity and also trial participants who were give the Incyclinide did not demonstrate a greater reduction in papules and pustules compared to patients on the placebo.